303 related articles for article (PubMed ID: 16540667)
21. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
22. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
23. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
24. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
Chiu HC; Chou DL; Huang CT; Lin WH; Lien TW; Yen KJ; Hsu JT
Biochem Pharmacol; 2011 Jun; 81(11):1263-70. PubMed ID: 21406185
[TBL] [Abstract][Full Text] [Related]
25. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
Lee C; Dhillon J; Wang MY; Gao Y; Hu K; Park E; Astanehe A; Hung MC; Eirew P; Eaves CJ; Dunn SE
Cancer Res; 2008 Nov; 68(21):8661-6. PubMed ID: 18974106
[TBL] [Abstract][Full Text] [Related]
26. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.
Borghouts C; Tittmann H; Delis N; Kirchenbauer M; Brill B; Groner B
Mol Cancer Res; 2010 Apr; 8(4):539-53. PubMed ID: 20371673
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Greulich H; Chen TH; Feng W; Jänne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR; Meyerson M
PLoS Med; 2005 Nov; 2(11):e313. PubMed ID: 16187797
[TBL] [Abstract][Full Text] [Related]
28. Stat3 activation is required for cell proliferation and tumorigenesis but not for cell viability in cutaneous squamous cell carcinoma cell lines.
Sumita N; Bito T; Nakajima K; Nishigori C
Exp Dermatol; 2006 Apr; 15(4):291-9. PubMed ID: 16512876
[TBL] [Abstract][Full Text] [Related]
29. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
Alvarez JV; Febbo PG; Ramaswamy S; Loda M; Richardson A; Frank DA
Cancer Res; 2005 Jun; 65(12):5054-62. PubMed ID: 15958548
[TBL] [Abstract][Full Text] [Related]
30. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation.
Pedersen MW; Pedersen N; Damstrup L; Villingshøj M; Sønder SU; Rieneck K; Bovin LF; Spang-Thomsen M; Poulsen HS
J Cell Biochem; 2005 Oct; 96(2):412-27. PubMed ID: 16075456
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis.
Ihara S; Kida H; Arase H; Tripathi LP; Chen YA; Kimura T; Yoshida M; Kashiwa Y; Hirata H; Fukamizu R; Inoue R; Hasegawa K; Goya S; Takahashi R; Minami T; Tsujino K; Suzuki M; Kohmo S; Inoue K; Nagatomo I; Takeda Y; Kijima T; Mizuguchi K; Tachibana I; Kumanogoh A
Cancer Res; 2012 Jun; 72(12):2990-9. PubMed ID: 22659452
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells.
Kim TH; Lee SY; Rho JH; Jeong NY; Soung YH; Jo WS; Kang DY; Kim SH; Yoo YH
Mol Cancer Res; 2009 Oct; 7(10):1645-54. PubMed ID: 19825993
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells.
Anagnostopoulou A; Vultur A; Arulanandam R; Cao J; Turkson J; Jove R; Kim JS; Glenn M; Hamilton AD; Raptis L
Cancer Lett; 2006 Oct; 242(1):120-32. PubMed ID: 16377083
[TBL] [Abstract][Full Text] [Related]
35. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes.
Rivat C; De Wever O; Bruyneel E; Mareel M; Gespach C; Attoub S
Oncogene; 2004 Apr; 23(19):3317-27. PubMed ID: 15077188
[TBL] [Abstract][Full Text] [Related]
36. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
[TBL] [Abstract][Full Text] [Related]
37. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.
Fletcher S; Drewry JA; Shahani VM; Page BD; Gunning PT
Biochem Cell Biol; 2009 Dec; 87(6):825-33. PubMed ID: 19935868
[TBL] [Abstract][Full Text] [Related]
38. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
[TBL] [Abstract][Full Text] [Related]
39. Cell transformation by the epidermal growth factor receptor and v-erbB.
Hayman MJ; Enrietto PJ
Cancer Cells; 1991 Aug; 3(8):302-7. PubMed ID: 1681843
[TBL] [Abstract][Full Text] [Related]
40. CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation.
Lin YC; Hung MS; Lin CK; Li JM; Lee KD; Li YC; Chen MF; Chen JK; Yang CT
Cancer Biother Radiopharm; 2011 Jun; 26(3):381-8. PubMed ID: 21711111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
